UTHR

SEC source: 0001104659-20-078807 · a4.xml · derivative · entry 2

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078807 · a4.xml · nonDerivative · entry 1

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001104659-20-078805 · a4.xml · derivative · entry 5

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,160

Underlying: Common Stock · 5,160 shares

Expires not disclosed

F6 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders.

F7 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F8 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001104659-20-078805 · a4.xml · derivative · entry 4

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

Underlying: Common Stock · 1,680 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078805 · a4.xml · derivative · entry 3

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078805 · a4.xml · nonDerivative · entry 1

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001104659-20-078804 · a4.xml · derivative · entry 3

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,360

Underlying: Common Stock · 3,360 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078804 · a4.xml · derivative · entry 2

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078804 · a4.xml · nonDerivative · entry 1

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001104659-20-078801 · a4.xml · derivative · entry 4

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,160

Underlying: Common Stock · 5,160 shares

Expires not disclosed

F6 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders.

F7 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F8 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001104659-20-078801 · a4.xml · derivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

Underlying: Common Stock · 1,680 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078801 · a4.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,300 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078801 · a4.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,960

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001104659-20-078798 · a4.xml · derivative · entry 2

Klein Katherine J · CIK 0001625073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,160

Underlying: Common Stock · 5,160 shares

Expires not disclosed

F5 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders.

F6 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F7 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001104659-20-078798 · a4.xml · derivative · entry 1

Klein Katherine J · CIK 0001625073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,680

Underlying: Common Stock · 1,680 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F3 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F4 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078796 · a4.xml · derivative · entry 3

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,360

Underlying: Common Stock · 3,360 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078796 · a4.xml · derivative · entry 2

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,600 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078796 · a4.xml · nonDerivative · entry 1

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001104659-20-078794 · a4.xml · derivative · entry 4

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,360

Underlying: Common Stock · 3,360 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders.

F5 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

F6 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares.

SEC source: 0001104659-20-078794 · a4.xml · derivative · entry 3

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,600 shares

Expires 2029-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

SEC source: 0001104659-20-078794 · a4.xml · nonDerivative · entry 1

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001104659-20-078793 · a4.xml · derivative · entry 2

CAUSEY CHRISTOPHER · CIK 0001237334 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,320

Underlying: Common Stock · 10,320 shares

Expires not disclosed

F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001127602-20-020459 · form4.xml · derivative · entry 16

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,834

Underlying: Common Stock · 10,000 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F7 · price: This transaction was executed in multiple trades at prices ranging from $127.535 to $127.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 397

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F6 · price: This transaction was executed in multiple trades at prices ranging from $126.49 to $127.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,314

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $125.465 to $126.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,198

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $124.44 to $125.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,727

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $123.435 to $124.315. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,449

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $122.22 to $123.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020459 · form4.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020324 · form4.xml · derivative · entry 19

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,834

Underlying: Common Stock · 10,000 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 14

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F12 · price: This transaction was executed in multiple trades at prices ranging from $122.22 to $122.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 13

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 563

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F11 · price: This transaction was executed in multiple trades at prices ranging from $121.14 to $121.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 12

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,272

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F10 · price: This transaction was executed in multiple trades at prices ranging from $120.13 to $121.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,942

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F9 · price: This transaction was executed in multiple trades at prices ranging from $119.13 to $120.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020324 · form4.xml · derivative · entry 18

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,834

Underlying: Common Stock · 10,000 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F8 · price: This transaction was executed in multiple trades at prices ranging from $120.63 to $120.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,311

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F7 · price: This transaction was executed in multiple trades at prices ranging from $119.63 to $120.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020324 · form4.xml · derivative · entry 17

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,834

Underlying: Common Stock · 10,000 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F6 · price: This transaction was executed in multiple trades at prices ranging from $119.075 to $119.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,066

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $118.08 to $119.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,976

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $117.055 to $117.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,235

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $116.04 to $117.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,492

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $114.86 to $115.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020324 · form4.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020107 · form4.xml · derivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,834

Underlying: Common Stock · 10,000 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

SEC source: 0001127602-20-020107 · form4.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F6 · price: This transaction was executed in multiple trades at prices ranging from $116.83 to $117.405. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001127602-20-020107 · form4.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,603

F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020.

F5 · price: This transaction was executed in multiple trades at prices ranging from $115.82 to $116.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.